ライフサイエンスコーパス: mumps

1 opment of prevention and control measures of mumps.

2 before the outbreak had an increased risk of mumps.

3 ative agent of the highly infectious disease mumps.

4 as to potential novel strategies to control mumps.

5 parotitis without laboratory confirmation is mumps.

6 ere high for measles and rubella but low for mumps.

7 rrelation for rubella and no correlation for mumps.

8 with and 715 without serological evidence of mumps.

9 f the participants had no detectable MBCs to mumps.

10 , varicella zoster virus (VZV), measles, and mumps.

11 ainst measles (1.63 vs 0.78 IU/mL; P = .03), mumps (168 vs 104 RU/mL; P = .03), and rubella (69 vs 45

12 varicella (14.0 days), smallpox (17.7 days), mumps (18.0 days), rubella (18.3 days), and pertussis (2

13 MuV-IA led to the typical clinical signs of mumps 2 weeks to 4 weeks postinfection.

14 hort: 3.3 months for measles, 2.7 months for mumps, 3.9 months for rubella, and 3.4 months for varice

15 re HAV (31.8%), HBV (63.8%), measles (1.4%), mumps (6.6%), and VZV (3.8%).

16 ols (measles, 100% vs 92% [95% CI, 84%-99%]; mumps, 97% [95% CI, 95%-100%] vs 81% [95% CI, 72%-93%];

17 Unusually large outbreaks of mumps across the United States in 2016 and 2017 raised q

18 The re-emergence of mumps among vaccinated young adults has become a global

19 to play a central role in the reemergence of mumps among vaccinated young adults.

20 together with functionally active "headless" mumps and Newcastle disease virus HN proteins, provide i

21 t a serious adverse event following measles, mumps and rubella (MMR) vaccination.

22 tion to live-virus vaccines such as measles, mumps and rubella (MMR) vaccination.

23 iseases, including smallpox, polio, measles, mumps and yellow fever.

24 ficity by using either live viruses (dengue, mumps, and measles viruses) or nucleic acid material (Ni

25 tures of homologous proteins in the measles, mumps, and Nipah viruses.

26 human and animal pathogens, such as measles, mumps, and parainfluenza viruses and the deadly henipavi

27 y index decreased by 8% for measles, 24% for mumps, and remained unchanged for rubella.

28 e average population immunities for measles, mumps, and rubella (92%, 87%, 92%) were similar to the p

29 Vaccination against measles, mumps, and rubella (MMR) and yellow fever (YF) with live

30 (PHIV) may not be protected against measles, mumps, and rubella (MMR) because of impaired initial vac

31 esitancy, using the case example of measles, mumps, and rubella (MMR) vaccination and measles.

32 ntrol and Prevention on coverage of measles, mumps, and rubella (MMR) vaccination, nonmedical exempti

33 Two doses of measles, mumps, and rubella (MMR) vaccine are 97% effective again

34 cted by the journal, suggested that measles, mumps, and rubella (MMR) vaccine causes autism.

35 Routinely, the first measles, mumps, and rubella (MMR) vaccine dose is given at 14 mon

36 The combined measles, mumps, and rubella (MMR) vaccine has been successfully a

37 ted data exist on the safety of the measles, mumps, and rubella (MMR) vaccine in adults.

38 m children 6 weeks after receipt of measles, mumps, and rubella (MMR) vaccine were tested for the abi

39 ad received one or two doses of the measles, mumps, and rubella (MMR) vaccine; and proportions with m

40 (SA-14-14-2), varicella (Varivax), measles, mumps, and rubella (MMR-II), measles (Attenuvax), rubell

41 neffects (negative controls) of the measles, mumps, and rubella and measles, mumps, rubella, and vari

42 ed with the separately administered measles, mumps, and rubella and varicella vaccines.

43 74.2% were positive by the Bio-Rad measles, mumps, and rubella IgG MFIs, respectively.

44 ined if revaccination with the live measles, mumps, and rubella vaccine (MMR) is associated with a lo

45 Measles, mumps, and rubella vaccine (MMR) or immune globulin (IG)

46 the risk of seizures compared with measles, mumps, and rubella vaccine administered with or without

47 in the United States, including (1) measles, mumps, and rubella vaccine and autism; (2) thimerosal, a

48 n participants who were vaccinated (measles, mumps, and rubella vaccine/tick-borne encephalitis vacci

49 mount of circulating antibodies for measles, mumps, and rubella was measured with enzyme immunoassays

50 pertussis, measles and rubella, or measles, mumps, and rubella) during pregnancy, confirming the fin

51 in infants vaccinated against MMR (measles, mumps, and rubella), but were confirmed in measles-infec

52 (Attenuvax) at 6 months of age and measles, mumps, and rubella, live attenuated (MMRII) vaccine at 1

53 Influenza, measles, mumps, and rubella, varicella, hepatitis A, meningococca

54 nfections per infectious person for measles, mumps, and rubella.

55 odominant protein), tetanus toxoid, measles, mumps, and rubella.

56 .5% of HCWs presumptively immune to measles, mumps, and VZV (a rubella IFA was unavailable).

57 gainst most viruses, including HAV, measles, mumps, and VZV (P < 0.05 for all).

58 Among HCWs fully vaccinated against measles, mumps, and VZV, Bio-Rad MFI/Bion IFA positivity rates we

59 were seropositive after vaccination for anti-mumps antibodies in both assays.

60 ses, we compared vaccine-induced preoutbreak mumps antibody levels between individuals who developed

61 ase patients generally had lower preoutbreak mumps antibody levels than nonpatients.

62 The moderate correlation between the anti-mumps antibody measurements obtained with PRNT and ELISA

63 s-rubella vaccines were used to compare anti-mumps antibody responses measured using an unenhanced PR

64 h-income countries since the introduction of mumps antigen-containing vaccines.

65 n serum indicates the onset of pancreatitis, mumps, cancer, stress, and depression.

66 Mumps case investigations included patient interviews, m

67 umps incidence by more than 99% and kept the mumps case numbers as low as hundreds of cases per year

68 verlapped and no cutoff points separated all mumps case patients from all nonpatients.

69 ody levels between individuals who developed mumps (case patients) and those who did not develop mump

70 United States experienced a 99% reduction in mumps cases following implementation of the 2-dose vacci

71 ved notification of more than 4000 suspected mumps cases in the second largest outbreak in the USA in

72 Mumps cases were defined using the 2012 Council of State

73 re confirmed in T cells derived from several mumps cases, and MuV-specific CD8+ T cells could be iden

74 rive held on campus before identification of mumps cases, we compared vaccine-induced preoutbreak mum

75 t mumps virus has been effective in reducing mumps cases.

76 nd 2017 raised questions about the extent of mumps circulation and the relationship between these and

77 Fifty-four (96%) cases had received >/=1 mumps-containing vaccine, 1 (2%) was unvaccinated due to

78 , 89% had previously received two doses of a mumps-containing vaccine, and 8% had received one dose.

79 For mumps control, high vaccine coverage and high population

80 ted States for persons at increased risk for mumps during outbreaks.

81 A, investigated between one and six cases of mumps each year.

82 97% (from 0.32 to 0.009) and admissions for mumps encephalitis decreased by 98% (from 0.60 to 0.01)

83 Admissions for measles and mumps encephalitis have decreased substantially.

84 High IgG avidity to mumps Enders strain was detected in sera of 59/71 partic

85 1 case patients, 22 nonpatients who reported mumps exposure but no mumps symptoms, and 103 nonpatient

86 The incidence of mumps has declined dramatically in high-income countries

87 n of the 2-dose vaccination program in 1989, mumps has resurged in the past 10 years.

88 kenpox, shingles, cold sores, mononucleosis, mumps, hepatitis B, plantar warts, positive tuberculosis

89 tudents had more than nine times the risk of mumps if they had received the second MMR dose 13 years

90 ivity for detection of anti-measles and anti-mumps IgG-class antibodies in presumptively immune or fu

91 of the 44 (5%) cases tested by serology were mumps IgM positive, and 27 of the 40 (68%) tested by RT-

92 Mumps IgM was detected in 17% of available specimens.

93 Mumps immunoglobulin M (IgM) testing was negative and re

94 festing, spatially replicated reemergence of mumps in England in the mid-2000s and pertussis post-198

95 However, recent large outbreaks of mumps in highly vaccinated populations suggest waning of

96 cination had reduced the annual incidence of mumps in the United States by more than 99%, with few ou

97 program implemented since the 1960s reduced mumps incidence by more than 99% and kept the mumps case

98 Widespread mumps vaccination has reduced mumps incidence dramatically; however, outbreaks still o

99 Mumps incidence in mainland China remains at a high leve

100 rubella induced high-avidity antibodies and mumps induced low-avidity antibodies after both vaccinat

101 vivirus NS5 protein or by YFV infection, and mumps infection did not alter CD4 mRNA or protein levels

102 f antibodies might contribute to measles and mumps infections in twice-MMR-vaccinated individuals.

103 Mumps is a highly contagious human disease, characterize

104 Mumps is a potentially severe viral infection.

105 Mumps is an acute viral illness that classically present

106 Mumps is mainly associated with mild symptoms, but sever

107 ggests continuous, undetected circulation of mumps locally and nationally, including multiple indepen

108 human viral infections, such as measles and mumps, may have their ancestry traced back to bats.

109 Seroprevalence rates of mumps, measles, and rubella determined by IgG enzyme-lin

110 for antibodies and memory B cells (MBCs) to mumps, measles, and rubella.

111 Mumps, measles, rubella, and varicella-zoster viruses (M

112 posure immunization with vaccines to prevent mumps, measles, rubella, varicella, pertussis, hepatitis

113 many of whom had the recommended 2 doses of mumps-measles-rubella (MMR) vaccine.

114 case patients) and those who did not develop mumps (nonpatients).

115 Abs did not neutralize or immune-precipitate mumps or yellow fever viruses.

116 inister a third dose of MMR vaccine improved mumps outbreak control and that waning immunity probably

117 In 2006, the largest mumps outbreak in the United States in 20 years occurred

118 es-mumps-rubella (MMR) vaccine in stemming a mumps outbreak is unknown.

119 However, a large mumps outbreak occurred in vaccinated populations in 200

120 In 2006, a mumps outbreak occurred on a university campus despite >

121 good and safe intervention for controlling a mumps outbreak.

122 During 2010-2015, multiple mumps outbreaks among highly vaccinated populations in c

123 Mumps outbreaks can occur in highly vaccinated populatio

124 In the past decade, multiple mumps outbreaks have occurred in the United States, prim

125 In recent years, many mumps outbreaks have occurred in vaccinated populations

126 Recently, numerous large-scale mumps outbreaks have occurred in vaccinated populations.

127 essed the epidemiological characteristics of mumps outbreaks with >=20 cases reported in the United S

128 future years signal an increased risk of new mumps outbreaks.

129 reby reducing the risk of future large-scale mumps outbreaks.

130 led connections between apparently unrelated mumps outbreaks.

131 important paramyxoviruses, such as measles, mumps, parainfluenza, Nipah, and Hendra viruses, infect

132 MuV epitopes could be detected in all tested mumps patients using peptide/HLA-A*02:01 dextramers.

133 Our method successfully anticipated mumps reemergence 4 years in advance, during which time

134 2954 cases of mumps related to the outbreak were identified during the

135 Admissions for mumps-related meningitis almost disappeared following in

136 ave been proposed as contributing factors to mumps resurgence.

137 The hypothesized link between the measles, mumps, rubella (MMR) vaccine and autism continues to cau

138 considered eligible to receive the measles, mumps, rubella (MMR) vaccine.

139 e, thimerosal, and/or receiving the measles, mumps, rubella (MMR) vaccine.

140 an 90% of all school types required measles, mumps, rubella, and hepatitis B vaccines for entering st

141 The BioPlex 2200 measles, mumps, rubella, and varicella (MMRV) IgG assay (Bio-Rad

142 rsely, completion by age 2 years of measles, mumps, rubella, and varicella immunization may offer imp

143 The combination measles, mumps, rubella, and varicella vaccine is associated with

144 In the analysis of vaccine type, measles, mumps, rubella, and varicella vaccine was associated wit

145 the measles, mumps, and rubella and measles, mumps, rubella, and varicella vaccines among children wh

146 s a qualitative diagnostic test for measles, mumps, rubella, and varicella virus immunity, in this st

147 gy that measures antibodies against measles, mumps, rubella, and varicella viruses simultaneously.

148 Immunity to measles, mumps, rubella, and varicella-zoster viruses (VZV; MMRV)

149 and 22 (1.9%) were seronegative for measles, mumps, rubella, and VZV, respectively, and 165 (14%) wer

150 Among HCWs presumptively immune to measles, mumps, rubella, and VZV, the Bio-Rad MFI was positive in

151 sonnel, including students, receive measles, mumps, rubella, hepatitis B, varicella, influenza, and p

152 I) of FSs in toddlers given MMRV and measles-mumps-rubella (MMR) and a national cohort study of vacci

153 ty of a 2-dose pediatric schedule of measles-mumps-rubella (MMR) or measles-mumps-rubella-varicella (

154 Increasing measles-mumps-rubella (MMR) vaccination among departing US trave

155 and Prevention and data on national measles-mumps-rubella (MMR) vaccination coverage during postelim

156 Measles-mumps-rubella (MMR) vaccination coverage with at least a

157 y and the effects of live attenuated measles-mumps-rubella (MMR) vaccination on disease activity in p

158 To protect young infants, measles-mumps-rubella (MMR) vaccination was offered to those age

159 n to introduction of PCR testing and measles-mumps-rubella (MMR) vaccination.

160 Measles-mumps-rubella (MMR) vaccinations have been offered to Fi

161 Measles-mumps-rubella (MMR) vaccine (given as either MMR or meas

162 research showing no link between the measles-mumps-rubella (MMR) vaccine and autism spectrum disorder

163 peared following introduction of the measles-mumps-rubella (MMR) vaccine in 1988.

164 on, the introduction of the two-dose measles-mumps-rubella (MMR) vaccine in 1996, and the implementat

165 ose of measles vaccine as a combined measles-mumps-rubella (MMR) vaccine in 1999 and the implementati

166 The effect of a third dose of the measles-mumps-rubella (MMR) vaccine in stemming a mumps outbreak

167 The measles-mumps-rubella (MMR) vaccine is effective in eliciting a

168 Primate schedule with or without the measles-mumps-rubella (MMR) vaccine, the MMR vaccine only, and t

169 coverage of students with 2 doses of measles-mumps-rubella (MMR) vaccine.

170 Two thousand immunized (2 doses of measles-mumps-rubella [MMR] vaccine) students and residents were

171 Measles-mumps-rubella dose 1 vaccination coverage ranged from 97

172 opies/mL, CD4% >/=15, and >/=1 prior measles-mumps-rubella vaccination (MMR) were given another MMR.

173 Widespread avoidance of Measles-Mumps-Rubella vaccination (MMR), with a consequent incre

174 ositive for measles and rubella; and measles-mumps-rubella vaccination coverage levels.

175 Typhoid or measles-mumps-rubella vaccination was associated with lower anti

176 all case series in Lancet connecting measles-mumps-rubella vaccinations with autism, small case serie

177 lla vaccine (V) dose given after one measles-mumps-rubella vaccine (MMR) dose (MMR + V), versus two M

178 A third measles-mumps-rubella vaccine (MMR) dose (MMR3) is recommended i

179 ponses and safety of a third dose of measles-mumps-rubella vaccine (MMR-3) in 150 young adults.

180 tates have received a second dose of measles-mumps-rubella vaccine (MMR2) at kindergarten entry.

181 sles vaccine to the incorporation of measles-mumps-rubella vaccine administered in the routine progra

182 collected and geocoded tweets about measles-mumps-rubella vaccine and classified their sentiment usi

183 ighly vaccinated populations (2-dose measles-mumps-rubella vaccine coverage >=85%).

184 mice exposed to the live-attenuated measles-mumps-rubella vaccine regardless of route of administrat

185 tory of vaccination with >2 doses of measles-mumps-rubella vaccine.

186 3 clinical trial (NCT01681992) of 2 measles-mumps-rubella vaccines were used to compare anti-mumps a

187 le of measles-mumps-rubella (MMR) or measles-mumps-rubella-varicella (MMRV) vaccine was assessed in c

188 ng combination vaccines, such as the measles-mumps-rubella-varicella (MMRV) vaccine, into immunizatio

189 efficacy of two doses of a combined measles-mumps-rubella-varicella vaccine (MMRV), one live attenua

190 lent varicella vaccine or a combined measles-mumps-rubella-varicella vaccine (MMRV).

191 MMR) vaccine (given as either MMR or measles-mumps-rubella-varicella vaccine and collectively referre

192 fever, varicella-zoster, multivalent measles/mumps/rubella, and two rotavirus live vaccines were part

193 rds review, and laboratory testing including mumps serology and RT-PCR.

194 CI, 60%-70%] vs 98% [95% CI, 95%-100%]), and mumps seropositivity (59% [95% CI, 55%-64%] vs 97% [95%

195 ization assay and rubella seroprotection and mumps seropositivity by enzyme immunoassay.

196 Predictors of rubella seroprotection and mumps seropositivity were similar.

197 To understand prior mumps seroprevalence and factors associated with the pre

198 outbreak potential, demonstrated using 2006 mumps seroprevalence data from Belgium and Belgian vacci

199 Mumps should be considered in patients with parotitis re

200 Protein sequences of measles- and mumps-specific circulating antibodies were encoded for b

201 The frequency of circulating mumps-specific MBCs was 5 to 10 times lower than measles

202 ion to the predominant circulating wild-type mumps strain (genotype G) were 6-fold lower than the GMT

203 y and the circulation of divergent wild-type mumps strains have been proposed as contributing factors

204 npatients who reported mumps exposure but no mumps symptoms, and 103 nonpatients who reported no know

205 hird dose of MMR vaccine had a lower risk of mumps than did those who had received two doses, after a

206 se was associated with a 78.1% lower risk of mumps than receipt of a second dose (adjusted hazard rat

207 entration of IgG was significantly lower for mumps than rubella.

208 of Health investigated all reported cases of mumps to ascertain exposure, travel, and vaccination his

209 Viral genomic data allowed us to reconstruct mumps transmission links not evident from epidemiologica

210 is B vaccine (HBV), Polio, Measles, Rubella, Mumps, trivalent MMR vaccine and Haemophilus influenza t

211 Widespread mumps vaccination has reduced mumps incidence dramatical

212 A mumps vaccination program implemented since the 1960s re

213 haracterize B and T cell immune responses to mumps vaccine and to develop strategies to improve the q

214 icating that it is a promising candidate for mumps vaccine development.

215 This outbreak raises questions about mumps vaccine effectiveness and potential waning immunit

216 derstanding of, and possibly for preventing, mumps vaccine failure.We identified for the first time 4

217 euroattenuation and neurovirulence, ensuring mumps vaccine safety has proven problematic, as demonstr

218 Mumps viral antigen was detected in parotid glands by im

219 luate the antigenic relationship between bat mumps virus (BMV) and the JL5 vaccine strain of mumps vi

220 Here we demonstrate that mumps virus (MuV) and vesicular stomatitis virus (VSV) a

221 Here we report that while PIV2, PIV5, and mumps virus (MuV) are sensitive to IFIT1, nonrubulavirus

222 Mumps virus (MuV) caused the most viral meningitis befor

223 Mumps virus (MuV) causes an acute infection in humans ch

224 The mumps virus (MuV) fusion protein (F) plays a crucial rol

225 The mumps virus (MuV) genome encodes a phosphoprotein (P) th

226 otype F has been the predominant genotype of mumps virus (MuV) in the last 20 years in mainland China

227 Mumps virus (MuV) infection may cause serious diseases i

228 unctional CD8+ T-cell response after natural mumps virus (MuV) infection that was not present after v

229 Mumps virus (MuV) is a highly contagious pathogen, and d

230 Mumps virus (MuV) is a reemerging paramyxovirus that cau

231 Mumps virus (MuV) is highly neurotropic and was the lead

232 circulating and emerging strains.IMPORTANCE Mumps virus (MuV) is the causative agent of the highly i

233 We systematically mapped the domains in mumps virus (MuV) P and investigated their interactions

234 iral proteins play in the phosphorylation of mumps virus (MuV) P.

235 To define mumps virus (MuV) proteins important for this process, v

236 To investigate the role of the mumps virus (MuV) SH protein in virulence, multiple stop

237 with high phylogenetic relatedness to human mumps virus (MuV) was identified recently at the nucleic

238 Mumps virus (MuV), a paramyxovirus containing a negative

239 The nucleocapsid protein (NP) of mumps virus (MuV), a paramyxovirus, was coexpressed with

240 luenza virus 3 (HPIV3), measles virus (MeV), mumps virus (MuV), and respiratory syncytial virus (RSV)

241 esults were obtained for the closely related mumps virus (MuV), except that MuV particles derived fro

242 failure.We identified for the first time 41 mumps virus (MuV)-specific HLA-A*02 epitopes.

243 breaks and to understand the pathogenesis of mumps virus (MuV).

244 ps virus (BMV) and the JL5 vaccine strain of mumps virus (MuVJL5), we rescued a chimeric virus bearin

245 scribe the generation of a novel recombinant mumps virus (rMuV) expressing HIV-1 Gag (rMuVgag) and me

246 proteins of Nipah virus, measles virus, and mumps virus also abolishes MDA5 interaction.

247 nfluenza virus type 2 (PIV2), PIV3, PIV5, or mumps virus and determined the abundances of individual

248 mber of cellular genes compared to wild-type mumps virus and increases cell death in infected cells,

249 , characterize different aspects of the anti-mumps virus antibody response after vaccination.

250 A recombinant mumps virus carrying the E95D mutation in its P and V pr

251 e-adjusted seroprevalence of IgG antibody to mumps virus during 1999-2004 was 90.0% (95% CI, 88.8%-91

252 on of three animal models with an isolate of mumps virus from a recent outbreak (MuV-IA).

253 Vaccination against mumps virus has been effective in reducing mumps cases.

254 Anti-mumps virus immunoglobulin M (IgM) antibodies were detec

255 sed antibody levels that may protect against mumps virus infection for longer than previously assumed

256 tly more participants were protected against mumps virus infection up to 1 year after vaccination (ie

257 MuV replication and transcription.IMPORTANCE Mumps virus is an important human pathogen.

258 Despite the presence of these multiple mumps virus lineages, the genomic data show that one lin

259 uently, PIV5 NP protein is incompatible with mumps virus M protein.

260 that interactions between this region of the mumps virus NP and its polymerase leads to exposure of t

261 Mumps virus NP protein harbors DWD in place of the DLD s

262 The structure of an empty mumps virus nucleocapsid-like particle is determined to

263 f the patient had laboratory confirmation of mumps virus or probable if they had clinical symptoms an

264 esent the best animal model for the study of mumps virus pathogenesis.

265 accine viruses, raising concern that certain mumps virus strains may escape vaccine-induced immunity.

266 efully selected group of genetically diverse mumps virus strains.

267 interferon-activated STAT1 or STAT2 protein, mumps virus V protein is unique in its ability to also t

268 utralizing test) against both the Jeryl Lynn mumps virus vaccine strain (hereafter, the "vaccine stra

269 In contrast, mumps virus was not inhibited by the expression of flavi

270 ublic health investigations with analysis of mumps virus whole genome sequences from 201 infected ind

271 including respiratory syncytial virus (RSV), mumps virus, and human metapneumovirus (HMPV).

272 to affect attenuation were detected in OPV, mumps virus, and varicella-zoster virus.

273 nfluenza virus (PIV) type 2, PIV3, PIV5, and mumps virus, as well as on the relative abundance of the

274 associated with the presence of antibody to mumps virus, data from the 1999-2004 National Health and

275 Mumps virus, enteroviruses (including human parechovirus

276 , parainfluenza virus type 5, measles virus, mumps virus, Hendra virus, and Nipah virus.

277 n enteroviruses/rhinoviruses, measles virus, mumps virus, Hepatitis A-E Virus, Chikungunya virus, den

278 ramyxovirus pathogens include measles virus, mumps virus, human respiratory syncytial virus, and the

279 Mumps virus, like other paramyxoviruses in the Rubulavir

280 myxoviruses parainfluenza virus 5 (PIV5) and mumps virus, M-NP interaction also contributes to effici

281 virus, Nipah virus, varicella-zoster virus, mumps virus, measles virus, lyssavirus, herpes simplex v

282 oteins of the paramyxoviruses measles virus, mumps virus, Newcastle disease virus, human parainfluenz

283 samples were seropositive for measles virus, mumps virus, or rubella virus antibodies, and there were

284 important viruses, including measles virus, mumps virus, parainfluenza viruses, respiratory syncytia

285 predict genes for 12 viruses: measles virus, mumps virus, rubella virus, respiratory syncytial virus,

286 k provides insight into a previously unknown mumps virus-host interaction.

287 mmunoglobulin G (IgG) antibody responses and mumps virus-neutralizing antibody responses (based on th

288 A mumps virus-specific enzyme immunoassay was used to meas

289 Mumps virus-specific immunoglobulin G (IgG) antibody res

290 least two doses of a vaccine containing the mumps virus.

291 Furthermore, we generated recombinant mumps viruses lacking expression of both the V protein a

292 hown that clinical isolate-based recombinant mumps viruses lacking expression of either the V protein

293 machinery in VLP budding was obtained, with mumps VLP production inhibited upon expression of domina

294 Efficient production of mumps VLPs occurred only when the M protein was coexpres

295 proteins and allowed efficient production of mumps VLPs.

296 enrolled during the 2015-2016 academic year, mumps was diagnosed in 259 students.

297 Fifty-six NYC residents with mumps were identified with onset between 12 January and

298 nd other symptoms clinically compatible with mumps were investigated, and demographic, clinical, labo

299 0, a total of 3502 outbreak-related cases of mumps were reported in New York City, two upstate New Yo

300 ses of parotitis are generally assumed to be mumps, which often requires a resource-intensive public